CSI uses 10-color flow cytometry – a sophisticated method for providing diagnosis, prognosis, and monitoring of malignancies with a relatively small sample size. With our skilled flow technologists and hematopathologists, we’re quickly able to identify emerging abnormalities and perform rare event analysis of patient-specific aberrant immunophenotypes.

Highlights include:

• An advanced 10-color platform yielding more information per tube
• Full characterization of low cellularity samples
• A proprietary panel design for reduced interference of co-expression
• Viability dye in all tubes to exclude non-viable events for improved analysis
• Kappa/Lambda combined in a single tube for B-cell abnormalities
• Client re-gating with FCS Express Reader
• Expert hematopathology consult services for difficult flow cytometry cases
• Antibody panel formulations personalized for each case to maximize accurate diagnoses
• Paroxysmal Nocturnal Hemoglobinuria (PNH) testing using high sensitivity FLAER-based analysis to diagnose and monitor PNH clones for treatment using eculizumab therapy

Long the cornerstone of genetic testing, cytogenetics analyzes the entire chromosome set for numerical and structural abnormalities such as chromosome additions, deletions and translocations. Identification of each abnormality aids diagnosis and treatment decisions for cancer patients. Cytogenetics requires interpretation by a skilled and experienced board-certified cytogeneticist–analysis of leukemias, lymphomas, and solid tumors often reveals otherwise undetectable chromosome abnormalities that might alter the diagnosis, prognosis, and therapeutic approach.

The cytogenetics team at CSI Laboratories is staffed by highly skilled PhDs and cytogenetic technologists. Each case is carefully reviewed to determine the most appropriate culturing methods and specific mitogens necessary to stimulate B-cell and T-cell lymphomas and plasma cell neoplasia samples in cytogenetic cultures. Our methods consistently provide our clients with reliable and informative cytogenetic results including tests on lymph nodes, which may be considered difficult samples to work with by other laboratories. All findings are correlated with other ancillary results to further help the pathologist in the morphologic evaluation of a particular neoplasm.

Highlights include:

• Chromosome analysis of leukemias, lymphomas, and solid tumors, as well as constitutional analysis
• Use of specific mitogens to stimulate B-cell and T-cell lymphomas
• Chromosome analyses of constitutional studies, including Products of Conception (POC)
• Lab approval by the Children’s Oncology Group (COG)
• Exceptional abnormality detection rates